{"id":262783,"date":"2010-02-01T13:38:14","date_gmt":"2010-02-01T18:38:14","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/02\/01\/17-billion-settlement-tops-jjs-2009-sales-of-coated-stents\/"},"modified":"2010-02-01T13:38:14","modified_gmt":"2010-02-01T18:38:14","slug":"1-7-billion-settlement-tops-jj%e2%80%99s-2009-sales-of-coated-stents","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/262783","title":{"rendered":"$1.7 Billion Settlement Tops J&J\u2019s 2009 Sales of Coated Stents"},"content":{"rendered":"

\"Gavel\"Boston Scientific said<\/a> today that it will pay Johnson & Johnson $1.7 billion (with a “b”!) to settle some longstanding patent disputes over stents.<\/p>\n

One interesting way to put that number in context: J&J’s total sales of drug-eluting stents last year amounted to $919 million, according to this SEC filing<\/a>. We haven’t seen full-year figures for Boston-Scientific, but the company reported<\/a> $411 million in world-wide sales of drug-eluting stents in the third quarter.<\/p>\n

The stent world has been working through lots of patent-infringement issues — Boston Scientific and J&J announced a separate, $716 million settlement last fall, and Medtronic last year agreed to pay Abbott $400 million to settle their patent battles.<\/p>\n

Today’s settlement isn’t the end of it. As Dow Jones Newswires notes<\/a>, litigation between the companies continues a lawsuit regarding Boston Scientific’s Promus-brand stents — the same stents that are sold by Abbott under the brand-name Xience.<\/p>\n

Photo: iStockphoto<\/em><\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Boston Scientific said today that it will pay Johnson & Johnson $1.7 billion (with a “b”!) to settle some longstanding patent disputes over stents. One interesting way to put that number in context: J&J’s total sales of drug-eluting stents last year amounted to $919 million, according to this SEC filing. We haven’t seen full-year figures […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-262783","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/262783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=262783"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/262783\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=262783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=262783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=262783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}